Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Patient website
A dedicated source of information designed especially for patients.
Patient support
Resources and downloadable booklets created to help you support your patients who have been prescribed Zejula (niraparib).
Patient resources
For your patients already on Zejula, we offer a Patient Support Programme and/or Homecare Medicines Service
GSK and HealthNet offer a 3-part service to help you monitor your patients throughout their treatment.
Want to discover more about how we can support you and your patients?
ZEJULA is indicated1
- as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Footnotes
MoA, mechanism of action; QoL, quality of life.
References
- ZEJULA Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
June 2023 | PM-GB-NRP-WCNT-220010 (V2.0)
